Integrase Inhibitors (INSTIs) for HIV: Uses, Side Effects & Considerations

Integrase strand transfer inhibitors (INSTIs) are a class of antiretroviral drugs that block HIV integrase, the enzyme that inserts viral DNA into the host cell genome—a critical, irreversible step in the viral lifecycle. By preventing integration, INSTIs halt viral replication with high potency. They are now the preferred anchor class for initial HIV treatment per major guidelines (DHHS, IAS-USA, EACS, WHO) due to their rapid viral suppression, high barrier to resistance (especially 2nd-gen), favorable tolerability, and few drug interactions.

Key INSTIs

  • First-generation: Raltegravir (RAL)—twice daily (or once-daily 1200 mg); low barrier to resistance; minimal drug interactions.
  • Second-generation: Dolutegravir (DTG), Bictegravir (BIC), Cabotegravir (CAB). Higher barrier to resistance; once-daily (oral); CAB is long-acting injectable (every 2 months with rilpivirine).

Common Side Effects

  • Nausea, diarrhea, headache, fatigue, dizziness, insomnia—generally mild and transient.
  • Weight gain: INSTIs (especially DTG, BIC, CAB) are associated with greater weight gain vs. NNRTIs/PIs, particularly in women, Black individuals, and those with low baseline CD4. Mechanism unclear; may involve improved health, metabolic changes, or CNS effects.
  • Neuropsychiatric: Insomnia, vivid dreams, anxiety, depression—more with DTG/RAL; less with BIC/CAB. Usually mild; switch if persistent.
  • Renal: DTG/BIC inhibit creatinine secretion (increases serum creatinine ~0.1–0.2 mg/dL without true GFR decline). Monitor eGFR.
  • Hypersensitivity: Rare but serious (rash, hepatitis, eosinophilia); more with RAL.

Contraindications & Precautions

  • Severe hepatic impairment: Use with caution; limited data.
  • Pregnancy: DTG preferred (extensive safety data); BIC/CAB not recommended (insufficient data). Neural tube defect signal with periconceptional DTG (Botswana Tsepamo study) was not confirmed in larger datasets; current guidelines support DTG use with counseling.
  • Drug interactions: INSTIs are metabolized by UGT1A1 and CYP3A4. Avoid strong inducers (rifampin, carbamazepine, phenytoin, St. John's wort) with DTG/BIC; dose-adjust RAL. Antacids/supplements with polyvalent cations (Mg, Al, Ca, Fe) reduce absorption—separate by 2h (DTG/BIC) or 4–6h (RAL).

Key Points

  • Taken once daily (oral) or every 2 months (injectable CAB/RPV), with or without food (except RAL HD with food).
  • Used in combination with 2 NRTIs (standard) or as 2-drug regimens (DTG/3TC, DTG/RPV, CAB/RPV) per guidelines.
  • Generally well-tolerated; monitor weight, renal function, neuropsychiatric symptoms.
  • Critical component of modern HAART, transforming HIV into a manageable chronic condition.

HIV & AIDS - Related Articles